Squarepoint’s Tenaya Therapeutics TNYA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$61K Sell
101,066
-558,181
-85% -$407K ﹤0.01% 4272
2026
Q2
$487K Buy
659,247
+310,979
+89% +$236K ﹤0.01% 3447
2026
Q1
$241K Buy
+348,268
New +$257K ﹤0.01% 3854
2025
Q4
– Sell
-36,253
Closed -$58.7K – 4899
2025
Q3
$58.7K Sell
36,253
-347,554
-91% -$350K ﹤0.01% 4203
2025
Q2
$235K Buy
383,807
+286,274
+294% +$146K ﹤0.01% 3871
2025
Q1
$55.6K Buy
97,533
+66,542
+215% +$65.6K ﹤0.01% 4326
2024
Q4
$44.3K Sell
30,991
-175,425
-85% -$393K ﹤0.01% 4863
2024
Q3
$398K Buy
206,416
+85,712
+71% +$242K ﹤0.01% 3266
2024
Q2
$374K Buy
120,704
+55,816
+86% +$231K ﹤0.01% 3285
2024
Q1
$339K Sell
64,888
-80,607
-55% -$386K ﹤0.01% 3310
2023
Q4
$471K Buy
145,495
+118,312
+435% +$255K ﹤0.01% 3046
2023
Q3
$69.3K Buy
+27,183
New +$114K ﹤0.01% 3604
2023
Q1
– Sell
-61,167
Closed -$123K – 3821
2022
Q4
$123K Buy
+61,167
New +$149K ﹤0.01% 2932

Other funds holding TNYA

Squarepoint's TNYA Position: Q3 2026 in Review

Squarepoint reduced its Tenaya Therapeutics (TNYA) stake by 85% in Q3 2026, selling an estimated $407K and leaving 101,066 shares worth $61K. The position accounts for ﹤0.01% of the portfolio, ranked #4272.

Squarepoint first reported a position in TNYA in Q4 2022 and has held it in 13 quarters since. The position peaked at $487K in Q2 2026. 33 funds tracked by Wall St. Rank hold TNYA as of Q3 2026.

  • Squarepoint held 101,066 shares of Tenaya Therapeutics worth $61K as of Q3 2026.
  • Squarepoint sold 558,181 Tenaya Therapeutics shares in Q3 2026, an estimated $407K.
  • Tenaya Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q3 2026, its #4272 holding.
  • Squarepoint first reported a position in Tenaya Therapeutics in Q4 2022 and has held it in 13 quarters since.
  • Squarepoint's Tenaya Therapeutics position peaked at $487K in Q2 2026.
  • 33 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q3 2026.

Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.